New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
about
Epidermal growth factor receptor blockers for the treatment of ovarian cancerAssessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles.Targeted therapies in epithelial ovarian cancer.Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cellsGPR30 predicts poor survival for ovarian cancerMiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation.Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.Clinical trial designs for testing biomarker-based personalized therapies.Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathwayL1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in MiceHigh levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancerModest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysisSigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer.Pattern of triple negative epithelial ovarian cancer in indigenous African womenSimilarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer.Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.Olaparib, PARP1 inhibitor in ovarian cancer.Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.Targeting Cyclin-Dependent Kinases in Ovarian Cancer.Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.Anticancer effects of chemokine receptor 4(CXCR4) gene silenced by CXCR4-siRNA in nude mice model of ovarian cancer.Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.CAR-T cell therapy in ovarian cancer: from the bench to the bedside.Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.Emerging drugs for ovarian cancer
P2860
Q24236143-7525552C-C8E0-4045-B688-303C9157EE1EQ30570691-7657D4FE-7501-412C-B53C-F3AE2CBC31A6Q33606699-91AE619F-9A19-470A-8571-9796AA46698AQ33829859-401081B6-47E6-40A5-BC7E-687B85BEEF4BQ34066297-AD6B5C28-8EA0-4D84-8FFD-1EDF86948294Q34089034-35747714-AC1A-4F8A-B749-2F410D1D7C60Q34166257-7C9D4AAD-4069-477D-8E96-C3D69C8E1E9EQ34785850-7D81C7C7-D8E3-48F4-8ADA-ADD823A23F9DQ34965037-BA766124-C3A3-4046-9546-F828BD789A3AQ34977663-A3AE7585-DCC9-4631-8291-D0582F21471FQ35632587-DB5CFD25-FAD9-4AF0-88C7-DF2D1388C3AEQ35892897-C5D69458-0845-4675-8BC5-5FD0FC687EB2Q36504170-9CCC9AFA-E130-4630-80EA-B16D9B1280ABQ37269642-EE4981CE-0527-41DF-ABFA-A5BEAB55D1B6Q37279268-0CE9037E-75B9-4544-AE79-4E00B1F3F2F7Q37384267-9C8CCF7F-E542-4908-9924-76A6336B2F12Q37687582-DDC2F32F-BE0C-4470-BB59-4DCF3A8EF98BQ37739569-43B3F704-D726-4F7C-AFFD-73EFF15411F1Q38025738-F1D79A4A-D01E-4D22-B7AA-35F41E94F8E0Q38715123-B99C9048-E6F0-4C11-9A28-8F2EF32F58D8Q38730812-974B879E-76F0-499D-9627-F9233B5B9DF6Q38826628-602263C1-841D-42D8-B01E-D4D95086BA6EQ38963532-6C7AA1D7-9E06-4544-9519-E629D5C2A12FQ39522079-66C977ED-5375-4C27-9D10-1FFB75A595A5Q42362802-29251AD5-45B9-4BCB-9CC7-A591F409FD6CQ46747718-ECCF13C5-0D91-413B-88A9-F1935867E7CDQ57903790-BE825773-7B3C-4753-AEF3-EF7EBF4D58BB
P2860
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
@en
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
@nl
type
label
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
@en
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
@nl
prefLabel
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
@en
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
@nl
P1476
New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.
@en
P2093
Ahmad Awada
Phuong Dinh
P304
P356
10.1016/J.CRITREVONC.2008.01.012
P577
2008-03-14T00:00:00Z